Acumen Pharmaceuticals (ABOS) EBITDA Yield: History & Chart

Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.

The EBITDA yield is N/A as of 2026-10-06T22:10:32.387Z.

Stored calculation inputs

Calculation as of: 2026-10-06T22:10:32.387Z.

Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.

TTM operating EBITDA · period ending 2026-06-30: -105,095,000
Quote market capitalization: 146,622,028
Total debt · period ending 2026-06-30: 31,569,000
Cash · period ending 2026-06-30: 59,443,000

FMP input reference: 5d81df243028a463df18dadfb6b81954a95dec5b5738e9798e17a16434fd93e0

EV/EBITDA|Earnings Yield|OCF Yield|FCF Yield|All Metrics

ABOS EBITDA Yield Metrics

EBITDA YIELD

N/A

ABOS Competitors' EBITDA Yield

ABOS

Acumen Pharmaceuticals, Inc.

Current

Market Cap

$146.62M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CDXS

Codexis, Inc.

vs ABOS

Market Cap

$146.28M

EBITDA Yield

N/A

TTM Avg

1.29%

3Y Avg

1.28%

5Y Avg

1.28%

FBIOP

Fortress Biotech, Inc.

vs ABOS

Market Cap

$146.27M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

AVXL

Anavex Life Sciences Corp.

vs ABOS

Market Cap

$148.27M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

VYGR

Voyager Therapeutics, Inc.

vs ABOS

Market Cap

$148.64M

EBITDA Yield

N/A

TTM Avg

17.25%

3Y Avg

38.66%

5Y Avg

34.07%

KRSA

Korsana Biosciences, Inc.

vs ABOS

Market Cap

$148.73M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ALXO

ALX Oncology Holdings Inc.

vs ABOS

Market Cap

$149.36M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NGEN

NervGen Pharma Corp. Common stock

vs ABOS

Market Cap

$143.84M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

TARA

Protara Therapeutics, Inc.

vs ABOS

Market Cap

$143.60M

EBITDA Yield

N/A

TTM Avg

2.27%

3Y Avg

2.27%

5Y Avg

2.27%

NYXH

Nyxoah S.A.

vs ABOS

Market Cap

$143.10M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EBITDA YIELD	TTM	3Y	5Y
Acumen Pharmaceuticals, Inc. (ABOS)	$146.62M	N/A	N/A	N/A	N/A
Codexis, Inc. (CDXS)vs ›	$146.28M	N/A	1.29%	1.28%	1.28%
Fortress Biotech, Inc. (FBIOP)vs ›	$146.27M	N/A	N/A	N/A	N/A
Anavex Life Sciences Corp. (AVXL)vs ›	$148.27M	N/A	N/A	N/A	N/A
Voyager Therapeutics, Inc. (VYGR)vs ›	$148.64M	N/A	17.25%	38.66%	34.07%
Korsana Biosciences, Inc. (KRSA)vs ›	$148.73M	N/A	N/A	N/A	N/A
ALX Oncology Holdings Inc. (ALXO)vs ›	$149.36M	N/A	N/A	N/A	N/A
NervGen Pharma Corp. Common stock (NGEN)vs ›	$143.84M	N/A	N/A	N/A	N/A
Protara Therapeutics, Inc. (TARA)vs ›	$143.60M	N/A	2.27%	2.27%	2.27%
Nyxoah S.A. (NYXH)vs ›	$143.10M	N/A	N/A	N/A	N/A

EBITDA Yield Formula & Definition

EBITDA Yield = TTM EBITDA / Enterprise Value

EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EBITDA Yield: N/A

ABOS EBITDA Yield Metrics

ABOS Competitors' EBITDA Yield

EBITDA Yield Formula & Definition

Related Metrics